tetano
Editor, Senior Moderator
Int Heart J
. 2022;63(6):1212-1214.
doi: 10.1536/ihj.22-344.
Second mRNA Vaccination of COVID-19 in a Patient Who Developed Pericarditis after the First Vaccination
Yutaro Oshima[SUP] 1 [/SUP], Tsuyoshi Nozue[SUP] 1 [/SUP], Sohei Takagi[SUP] 1 [/SUP], Toshiki Asada[SUP] 1 [/SUP], Toshitsugu Gamou[SUP] 1 [/SUP], Taku Iwaki[SUP] 1 [/SUP], Ichiro Michishita[SUP] 1 [/SUP]
Affiliations
Abstract
The coronavirus infection 2019 (COVID-19) pandemic has led to the development of mRNA vaccines with proven efficacy. However, it remains unclear whether patients who developed pericarditis after the first COVID-19 mRNA would be fit to receive the second vaccination. Herein, we present the case of a 64-year-old man who visited our emergency department with substernal chest discomfort that began 4 days after his first mRNA COVID-19 vaccination. Acute pericarditis was diagnosed based on symptoms and ST-segment elevation on an electrocardiogram. Chest pain improved 2 days after treatment.Since there are no guidelines on whether to administer an additional vaccination to a patient who developed pericarditis after the initial vaccination, we considered whether or not to administer the additional vaccination. We informed the patient about the risks and benefits and decided to administer the second dose. He did not experience any major adverse reactions. The indications for the second vaccination need to be thoroughly considered.
. 2022;63(6):1212-1214.
doi: 10.1536/ihj.22-344.
Second mRNA Vaccination of COVID-19 in a Patient Who Developed Pericarditis after the First Vaccination
Yutaro Oshima[SUP] 1 [/SUP], Tsuyoshi Nozue[SUP] 1 [/SUP], Sohei Takagi[SUP] 1 [/SUP], Toshiki Asada[SUP] 1 [/SUP], Toshitsugu Gamou[SUP] 1 [/SUP], Taku Iwaki[SUP] 1 [/SUP], Ichiro Michishita[SUP] 1 [/SUP]
Affiliations
- PMID: 36450560
- DOI: 10.1536/ihj.22-344
Abstract
The coronavirus infection 2019 (COVID-19) pandemic has led to the development of mRNA vaccines with proven efficacy. However, it remains unclear whether patients who developed pericarditis after the first COVID-19 mRNA would be fit to receive the second vaccination. Herein, we present the case of a 64-year-old man who visited our emergency department with substernal chest discomfort that began 4 days after his first mRNA COVID-19 vaccination. Acute pericarditis was diagnosed based on symptoms and ST-segment elevation on an electrocardiogram. Chest pain improved 2 days after treatment.Since there are no guidelines on whether to administer an additional vaccination to a patient who developed pericarditis after the initial vaccination, we considered whether or not to administer the additional vaccination. We informed the patient about the risks and benefits and decided to administer the second dose. He did not experience any major adverse reactions. The indications for the second vaccination need to be thoroughly considered.